← All trials
NCT05225285
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 21, 2022
- Primary completion
- Jun 21, 2022
- Completion date
- Mar 21, 2023
- First posted
- Feb 4, 2022
- Last posted
- Feb 4, 2022
- Enrollment
- 1120
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Federal University of Espirito SantoLead sponsor
- Butantan InstituteCollaborator
- Federal University of Espirito SantoReponsible party - principal investigator
- Federal University of Espirito SantoSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.